Wei Junying, Sun Jianhui, Zeng Jiawei, Ji Enhui, Xu Jing, Tang Chunyu, Huo Hairu, Zhang Yi, Li Hongmei, Yang Hongjun
Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, China.
Department of Clinical Laboratory, Mianyang Central Hospital, Mianyang, China.
Front Pharmacol. 2021 Nov 18;12:604009. doi: 10.3389/fphar.2021.604009. eCollection 2021.
Viral pneumonia is one of the most serious respiratory diseases, and multicomponent traditional Chinese medicines have been applied in the management of infected patients. As a representative TCM, HouYanQing (HYQ) oral liquid shows antiviral activity. However, the unclear mechanisms, as well as the ambiguous clinical effects, limit widespread application of this treatment. Therefore, in this study, a proteomics-based approach was utilized to precisely investigate its efficacy. Based on the efficacy evaluation of HYQ in a mouse model of pneumonia caused by influenza A virus (H1N1) and the subsequent proteomics analysis, specific signatures regulated by HYQ treatment of viral pneumonia were identified. Experimental verifications indicate that HYQ may show distinctive effects in viral pneumonia patients, such as elevated galectin-3-binding protein and glutathione peroxidase 3 levels. This study provides a precise investigation of the efficacy of a multicomponent drug against viral pneumonia and offers a promising alternative for personalized management of viral pneumonia.
病毒性肺炎是最严重的呼吸道疾病之一，多成分中药已应用于感染患者的治疗。作为一种代表性的中药，喉咽清（HYQ）口服液具有抗病毒活性。然而，其作用机制尚不明确，临床效果也不确切，限制了该疗法的广泛应用。因此，在本研究中，采用基于蛋白质组学的方法来精确研究其疗效。基于喉咽清在甲型流感病毒（H1N1）引起的小鼠肺炎模型中的疗效评估及后续的蛋白质组学分析，确定了喉咽清治疗病毒性肺炎所调节的特定特征。实验验证表明，喉咽清可能对病毒性肺炎患者有独特的作用，如半乳糖凝集素-3结合蛋白和谷胱甘肽过氧化物酶3水平升高。本研究精确调查了一种多成分药物对病毒性肺炎的疗效，并为病毒性肺炎的个性化治疗提供了一种有前景的替代方案。
